Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. J of Skin 2022, 6 (2), s1. https://doi.org/10.25251/skin.6.supp.1.